Drugs / Vivaglobin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00701662 | Nov 2007 → Jan 2009 | multifocal motor neuropathy | CSL Behring | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00520494 | Mar 2007 → Oct 2008 | common variable immunodeficiency | CSL Behring | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-10-07 | CSL Behring | Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin as First-Line Therapy for Primary Immunodeficiency csl.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vivaglobin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00701662 ↗ |
| Modality | Protein / enzyme biologic | “Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.” NCT00520494 ↗ |
| Route | Subcutaneous | “Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.” NCT00520494 ↗ |